Overview

Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Evaluate safety, tolerability and antiviral response of ACH-0141625 compared to Standard of Care in HCV positive subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Achillion Pharmaceuticals
Alexion Pharmaceuticals
Treatments:
Antiviral Agents
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin